



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/682,303
		Filing Date	October 9, 2003
		First Named Inventor	Trillo
		Art Unit	Unknown
		Examiner Name	Unknown
Total Number of Pages in This Submission		Attorney Docket Number	ANA-5955

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): - Acknowledgement Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement *	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
* Form PTO/SB/08A and 08B (four pages) with reference copies (4 patents and 28 publications)		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Eric A. Meade, Reg. No. 42,876
Signature	<i>E. A. Meade</i>
Date	January 7, 2004

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Eric A. Meade		
Signature	<i>E. A. Meade</i>	Date	January 7, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**CERTIFICATE OF MAILING**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON JANUARY 7, 2004

*E. C. Meade*

ERIC A. MEADE

REGISTRATION NO. 42,876

Attorney Docket No. **ANA-5955**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Trillo et al.

Serial No.: 10/682,303

Filed: October 9, 2003

For: Method for Cardioprotection and Neuroprotection by Intravenous Administration of Halogenated Volatile Anesthetics

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.56**

Applicants herein make available to the Patent and Trademark Office copies of the references, listed on the included Form PTO-1449.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

**(1) This Information Disclosure Statement is being filed:**

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- before** the mailing date of a first Office Action on the merits.
- after** the mailing date of the first Office Action on the merits, but **before** the mailing date of

a Final Action under 37 CFR 1.113,  
a Notice of Allowance under 37 CFR 1.311, or

an action that otherwise closes prosecution,  
and is accompanied by either:

- the Statement under 37 CFR 1.97(e) (see "Statement" below), **or**
- the fee under 37 CFR 1.17(p).

**after** the mailing date of

- a Final Action under 37 CFR 1.113,
- a Notice of Allowance under 37 CFR 1.311, or
- an action that otherwise closes prosecution,,

and is accompanied by both:

- the Statement under 37 CFR 1.97(e) (see "Statement" below), **and**
- the fee under 37 CFR 1.17(p).

**(2) Statement**

- The **undersigned attorney** hereby states that each item information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement. *(If this box is checked, do not check any further Statement boxes.)*

**or**

- The **person signing immediately below** hereby states that no item of information contained in the Supplemental Information Disclosure was cited in any communication from any foreign patent office in any counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

*The person making the statement is:*

- the inventor(s) who sign(s) below:

---

*Signature of the Inventor(s)*

---

*Typed or Printed Name of the Inventor(s)*

---

**or**

- a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an

obligation to assign the application (37 CFR 1.565(c)) and who signs below:

---

*Signature of the Person(s)*

---

*Typed or Printed Name of the Person*

---

*Address of Person Signing*

---

**or**

the undersigned attorney who signs on the basis of the information:

- supplied by the inventor(s).
- supplied by an individual designated in 37 CFR 1.56(c).
- in the attorney's file.

---

*Signature of the Attorney (4) Fees*

**No Fee** is owed by the applicants.

**The IDS Fee of \$180.00** under 37 CFR 1.17(p) is enclosed herewith.

**(5) Method of Payment of Fees**

Attached is a check in the amount of \$\_\_\_\_\_.

Applicants hereby authorize the Commissioner to charge the **\$180.00** IDS Fee to Deposit Account No. 04-0480.



Application Serial No. 10/682,303  
Docket No. ANA-5955

**Authorization to Charge Additional Fees**


Applicants hereby authorize the Commissioner to charge any additional fees deemed required for consideration of this Paper to Deposit Account No. 04-0480.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Eric A. Meade  
Registration No. 42,876

DECHERT LLP  
A Pennsylvania Limited Liability Partnership  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, New Jersey 08543-5218  
Phone: (609) 620-3248  
Fax: (609) 620-3259



JAN 09 2004

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTC

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**(Use as many sheets as necessary)**

Sheet 1 of 4

**Complete if Known**

Application Number	10/682,303
Filing Date	October 9, 2003
First Named Inventor	Trillo, Raul
Art Unit	unknown
Examiner Name	unknown

Attorney Docket Number **ANA-5955**

**U. S. PATENT DOCUMENTS**


**FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

**Complete if Known**

Application Number	10/682,303
Filing Date	October 9, 2000
First Named Inventor	Trillo, Raul
Art Unit	unknown
Examiner Name	unknown

Attorney Docket Number

ANA-5955

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		WERNER ET AL; Sevoflurane Improves Neurological Outcome After Incomplete Cerebral Ischaemia in Rats; Br J Anaesth.; Dec 1995; pp756-760; 75(6).	
		BEIRNE ET AL; Effect of Halothane in Cortical Cell Cultures Exposed to N-methyl-D-aspartate; Neurochem Res. Jan 1998; pp 17-23; 23(1).	
		GRADY ET AL; Correlation of Regional Cerebral Blood Flow with Ischemic Electroencephalographic Changes ...; Anesthesiology; April 1998; 88(4); pp 892-897.	
		SOONTHON-BRANT ET AL; Fentanyl Does Not Increase Brain Injury after Focal Ischemia in Rats; Anesth Analg.; January 1999; pp 49-55; 88(1).	
		PATEL ET AL; Isoflurane and Pentobarbital Reduce the Frequency of Transient Ischemic Depolarizations During Focal Ischemia in Rats; Anesth Analg.; Apr 1998; pp 773-80; 86(4).	
		MIURA ET AL; Differential Effects of Anesthetic Agents on Outcome from Near Complete but Not Incomplete Global Ischemia in the Rat; Anesthesiology Aug 1998; pp 289-291; 89(2).	
		DE HERT ET AL; Contraction-Relaxation Coupling and Impaired Left Ventricular Performance in Coronary Surgery Patients; Anesthesiology Mar 1999; pp 748-57; 90(3).	
		DE HERT ET AL; Length-Dependent Regulation of Left Ventricular Function in Coronary Surgery Patients; Anesthesiology Aug 1999; pp 379-87; 91(2).	
		DE HERT ET AL; The Effects of Beta-Adrenergic Stimulation on the Length-Dependent Regulation of Myocardial...; Anesth Analg. Oct 1999; pp 835-42; 89(4).	
		ENGELHARD ET AL; Desflurane and Isoflurane Improve Neurological Outcome after Incomplete Cerebral Ischaemia in Rats; Br J Anaesth. Sep 1999; pp 415-21; 83(3).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

4

**Complete if Known**

Application Number	10/682,303
Filing Date	October 9, 2000
First Named Inventor	Trillo, Raul
Art Unit	unknown
Examiner Name	unknown

Attorney Docket Number

ANA-5955

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BELHOMME ET AL; Evidence for Preconditioning by Isoflurane in Coronary Artery Bypass Graft Surgery; Circulation Nov 9, 1999; pp II-340-344.	
		WENKER OLIVER C; Review of Currently Used Inhalation Anesthetics : Part I; The Internet Journal of Anesthesiology 1999; vol 3(2).	
		WENKER OLIVER C; Review of Currently Used Inhalation Anesthetics : Part II; The Internet Journal of Anesthesiology 1999; vol 3(3).	
		KIMBRO ET AL; Isoflurane and Pentobarbital Reduce AMPA Toxicity In Vivo in the Rat Cerebral Cortex; Anesthesiology Mar 2000; pp 806-12; 92(3).	
		KAWAGUCHI ET AL; Isoflurane Delays but Does Not Prevent Cerebral Infarction In Rats Subjected to Focal Ischemia; Anesthesiology May 2000; pp 1335-42; 92(5).	
		ROSCOE ET AL; Isoflurane, but Not Halothane, Induces Protection of Human Myocardium via Adenosine A1 Receptors...; Anesthesiology Jun 2000; pp 1692-1701; 92(6).	
		TOLLER ET AL; Sarcolemmal and Mitochondrial Adenosine Triphosphate-Dependent Potassium Channels; Anesthesiology Jun 2000; pp 1731-1739; 92(6).	
		NELLGARD ET AL; Anesthetic Effects on Cerebral Metabolic Rate Predict Histological Outcome From...; Anesthesiology Aug 2000; pp 431-436; 93(2).	
		HANS ET AL; Neuroprotection with Anaesthetic Agents; Current Opinion in Anaesthesiology 2001; pp 491-496; vol. 14.	
		HAROUN-BIZRI ET AL; Does Isoflurane Optimize Myocardial Protection During Cardiopulmonary Bypass? J Cardiothorac Vasc Anesth. Aug 2001; pp 418-21; 15(4).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	4	of	4	Attorney Docket Number	ANA-5955

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		HANOUZ ET AL; Mechanisms of Desflurane-Induced Preconditioning in Isolated Human Right Atria in Vitro; Anesthesiology Jul 2002; pp 33-41; 97(1).			
		DE HERT ET AL; Sevoflurane but Not Propofol Preserves Myocardial Function in Coronary Surgery Patients; Anesthesiology Jul 2002; pp 42-49; 97(1).			
		WARLTIER ET AL; Anesthetic Preconditioning; Serendipity and Science; Anesthesiology Jul 2002; pp 1-3; 97(1).			
		CUIGNET ET AL; A Second-Generation Blood Substitute (Perflubron Emulsion) Increases the Blood Solubility of Modern Volatile ...; Anesth Analg Aug 2002; pp 368-372.			
		PARK KW; Cardiovascular Effects of Inhalational Anesthetics; Int. Anesthiol Clin; Winter 2002; pp 1-14; 40(1).			
		DE HERT ET AL; Effects of Propofol, Desflurane, and Sevoflurane on Recovery of Myocardial Function...; Anesthesiology Aug 2003; pp 314-23; 99(2).			
		CONZEN ET AL; Sevoflurane Provides Greater Protection of the Myocardium Than Propofol In Patients Undergoing Off-Pump...; Anesthesiology Oct 2003; pp 826-33; 99(4).			
		ENGELHARD ET AL; The Effect of Sevoflurane and Propofol On Cerebral Neurotransmitter Concentrations During Cerebral Ischemia in Rats; Anesth Analg. Oct 2003, pp 1155-61; 97(4)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.